Collaborations and Other Relationships - Additional Information (Details) - USD ($) $ in Millions		12 Months Ended
	Sep. 04, 2020	Jan. 02, 2022	Jan. 03, 2021	Dec. 29, 2019	Jan. 31, 2015
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Revenues		$ 2,042.8	$ 1,766.2	$ 1,801.5
Research and development expense		126.2	112.9	98.0
Accounts payable		181.0	146.2
Collaborations
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Revenues		21.9	22.9	23.9
Grifols Diagnostic Solutions, Inc.
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Pre-tax net profit		35.5	32.7	46.8
Quotient Limited
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Potential Payments Upon Achievement Of Certain Cumulative Revenue Milestones					$ 25.0
Sales to Quotient				0.3
Joint Business | Grifols Diagnostic Solutions, Inc.
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Net profit shared under joint venture, before tax		57.4	55.6	70.7
Letter Agreement | Quotient Limited
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Non-refundable upfront payment	$ 7.5
Research and development expense			7.5
Inventories, purchased		22.4	21.1	$ 20.3
Accounts payable		4.1	2.3
Sales to Quotient		$ 0.2	$ 0.3
Letter Agreement | Quotient Limited | Maximum
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Potential additional payments upon achievement of certain regulatory milestones and commercial sales benchmarks	60.0
Potential Payments Upon Achievement Of Certain Cumulative Revenue Milestones	$ 25.0